NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021

by Ed Johnson
September 11, 2021
A A

–Final results from PROviDE, a long-term, real-world study, evaluating the effectiveness of DUODOPA® (levodopa-carbidopa intestinal gel) in patients with advanced Parkinson’s disease
–Additional poster presentations planned on the real-world efficacy and safety of BOTOX® (onabotulinumtoxinA) for the treatment of spasticity and cervical dystonia
–Research highlights AbbVie’s continued focus on advancing the management of movement disorders

NORTH CHICAGO, Ill., Sept. 10, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22. More than 20 abstracts across disease states, including Parkinson’s disease, spasticity and cervical dystonia, will be presented.

“At AbbVie, we are committed to addressing the unmet needs of people living with a wide range of movement disorders,” said Sebastian Sorsaburu, MD, vice president, global specialty care medical affairs, AbbVie. “Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.”

Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.

Key AbbVie abstracts for the MDS Virtual Congress 2021, which will all be available as virtual e-posters beginning at 8:00 a.m. CDT on September 10, are outlined below.

Key AbbVie Abstracts at MDS 2021
Abstract Title
DUODOPA® Abstracts
Dyskinesia, Pain, and Quality of Life in Parkinson’s Disease: Post Hoc Analysis from the DYSCOVER Study
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients with Motor Fluctuations and Dyskinesia Managed with Oral Dopaminergic Therapies Versus Device-Aided Therapies
Impact on Dyskinesia in Advanced Parkinson’s Disease Patients Treated with LCIG: Analysis from the COSMOS Study
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients with Advanced Parkinson’s Disease
Long-Term Real-World Effectiveness of Carbidopa/Levodopa Enteral Suspension After 36 Months of Treatment Initiation: Final Results from PROviDE Study
Levodopa/Carbidopa Intestinal Gel (LCIG) Reduces Fluctuations and Shortens Time to On Without Troublesome Dyskinesia in Advanced Parkinson’s Disease: Post-Hoc Analyses of 54-week LCIG-Monotherapy Trial
Real-World Characteristics of Advanced Parkinson’s Disease Patients Initiating Carbidopa/Levodopa Enteral Suspension
Impact of Device-Aided Therapies on QoL and Off-Time Improvement in Advanced Parkinson’s Disease Patients: Comparative Effectiveness Results from a Bayesian Network Meta-Analysis
Overview of the Population of Patients with Advanced Parkinson’s Disease (aPD) Initiating Therapy with Levodopa-Carbidopa Intestinal Gel (LCIG): POMPE-PARK Study on French Health Insurance Data (2013-2017)
BOTOX® Abstracts
OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study
Neutralizing Antibody Conversion with OnabotulinumtoxinA from Global Studies Across Multiple Indications with a Focus on Movement Disorders: A Meta-Analysis
Benefits of Treatment with OnabotulinumtoxinA in Naive and Non-Naive Patients with Cervical Dystonia are Sustained Over Time: Preliminary Completer Analysis from CD PROBE
Impact of Disease Severity on Presentation Subtype and OnabotulinumtoxinA Utilization in Patients with Cervical Dystonia: Results from the CD PROBE Completer Population
A Cell-Penetrating Peptide (CPP) Did Not Decrease 150-kDa BoNT/A Toxin Adsorption to Surfaces or Increase Toxin Potency or Duration in a Prototype Formulation
OnabotulinumtoxinA Exhibits Greater Efficacy Compared to Purified Botulinum Neurotoxin A (Bont/A-150 KDA) in Peripheral Pain Models
Disease State Abstracts
Classification of Advanced Parkinson’s Disease in OBSERVE-PD Patients Based on the MANAGE-PD Screening Tool
COVID-19 Pandemic Impact on Advanced Parkinson’s Disease in the US
Current Perspectives on the Management of Cervical Dystonia Among Global Clinicians
Tags: < Corporate Events
ShareTweetShareSend

Related Industries

Healthcare

Medtronic recommends rejection of below-market mini-tender offer by TRC Capital Investment Corporation

January 26, 2023
Healthcare

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

January 25, 2023
Healthcare

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

January 18, 2023
Healthcare

AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

January 11, 2023
Healthcare

Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders

January 7, 2023
Healthcare

Michelle Quinn Named Acting General Counsel for BD

January 7, 2023

Microsoft and Qcells announce strategic alliance to curb carbon emissions and power the clean energy economy

January 26, 2023

...

Ford Joins the Virtual Power Plant Partnership as a Founding Member to Support Grid Resiliency and Emissions Reductions

January 11, 2023

...

Emerson Announces Premium, All-Cash Proposal to Acquire National Instruments for $53 Per Share

January 18, 2023

...

SKF increases regionalization in North America

February 3, 2023

...

Intel Board of Directors Appoints Frank D. Yeary as New Independent Chair

January 24, 2023

...

Honeywell Identifies Top Building Technology Trends For 2023

January 11, 2023

...

Kohler Co. Appoints Laura Kohler as Company’s First Chief Sustainability and DEI Officer

January 20, 2023

...

Cargill Announces CFO Transition

January 10, 2023

...

Michelle Quinn Named Acting General Counsel for BD

January 7, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

INDUSTRIES

  • Aero
  • Agriculture
  • ALL
  • Automotive
  • Business Service
  • Chemical
  • Construction
  • Construction Materials
  • Consumer
  • Education
  • Energy
  • Entertainment
  • Environmental
  • F&B
  • Financial
  • Healthcare
  • Hospitality
  • Industrial
  • IT
  • IT Hardware
  • Logistic
  • Metal & Mining
  • Packaging & Paper
  • Rail
  • Real Estate
  • Telecom

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.